| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
1278 |
| issn |
0028-4793
1533-4406 |
| issueIdentifier |
13 |
| pageRange |
1277-1278 |
| publicationName |
The New England journal of medicine |
| startingPage |
1277 |
| bibliographicCitation |
Lister TA. Who should receive myeloablative therapy for lymphoma? N Engl J Med. 2004 Mar 25;350(13):1277–8. doi: 10.1056/nejmp048007. PMID: 15044635. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7db4ed1dae3f3a8a062cd3c63d530189 |
| date |
2004-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1056/nejmp048007
https://pubmed.ncbi.nlm.nih.gov/15044635 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1533-4406
https://portal.issn.org/resource/ISSN/0028-4793
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5985 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Who Should Receive Myeloablative Therapy for Lymphoma? |
| discusses |
http://id.nlm.nih.gov/mesh/M0005485
http://id.nlm.nih.gov/mesh/M0006784
http://id.nlm.nih.gov/mesh/M0022676
http://id.nlm.nih.gov/mesh/M0017465 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D033581
http://id.nlm.nih.gov/mesh/D008223Q000628
http://id.nlm.nih.gov/mesh/D000971Q000008 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D014750Q000008
http://id.nlm.nih.gov/mesh/D004317Q000008
http://id.nlm.nih.gov/mesh/D003520Q000008
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D003131
http://id.nlm.nih.gov/mesh/D011241Q000008 |